EU ministers urge incentives for R&D into new antibiotics
This article was originally published in SRA
R&D into new antibiotics has declined significantly and will probably not yield enough new products to meet medical needs within the next five to ten years. There is, therefore, an “urgent need” to create incentives for research into new therapeutics, according to European Union health ministers.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.